Review Article| Volume 107, ISSUE 2, P271-284, March 2023

Download started.


Breast Cancer

Risk Assessment, Screening, and Primary Prevention


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Medical Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Center for Disease Control
        Breast Cancer Statistics.
        (Available at:) (Accessed May 30, 2022)
        • American Cancer Society
        Key Statistics for Breast Cancer.
        (Available at:) (Accessed May 30, 2022)
        • DeSantis C.
        • Ma J.
        • Bryan L.
        • et al.
        Breast cancer statistics, 2013.
        CA Cancer J Clin. 2014; 64 (Accessed May 30, 2022): 52-62
        • Siegel R.
        • Ward E.
        • Brawley O.
        • et al.
        Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.
        CA Cancer J Clin. 2011; 61: 212-236
        • Colditz G.A.
        • Bohlke K.
        Priorities for the primary prevention of breast cancer.
        CA Cancer J Clin. 2014; 64: 186-194
        • Nelson H.D.
        • Smith M.B.
        • Griffin J.C.
        • et al.
        Use of medications to reduce the risk for primary breast cancer: a systematic review for the US Preventive Services Task Force.
        Ann Intern Med. 2013; 158: 604-614
        • Owens D.K.
        • Davidson K.W.
        • Krist A.H.
        • et al.
        Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement.
        Jama. 2019; 322: 652-665
        • National Comprehensive Cancer Network
        NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian, version 1.
        (Available at:) (Published online October 3, 2017. Accessed March 11, 2018)
        • Nattinger A.B.
        • Mitchell J.L.
        Breast cancer screening and prevention.
        Ann Intern Med. 2016; 164: ITC81
        • Sprague B.
        • et al.
        Proportion of invasive breast cancer attributable to risk factors modifiable after menopause. Am J Epidemiol. 168(4.
        (Available at:) (Accessed May 30, 2022)
        • Moskowitz C.S.
        • Chou J.F.
        • Wolden S.L.
        • et al.
        Breast cancer after chest radiation therapy for childhood cancer.
        J Clin Oncol Off J Am Soc Clin Oncol. 2014; 32: 2217-2223
        • Schnitt S.J.
        Benign breast disease and breast cancer risk: morphology and beyond.
        Am J Surg Pathol. 2003; 27: 836-841
      1. Bernstein, L et al. Lifetime recreational exercise activity and breast cancer risk among black women and white women. J Natl Cancer Inst. 97(22).

      2. Marmot M, Atinmo T, Byers T, et al. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Published online 2007.

        • Chen W.Y.
        • Rosner B.
        • Hankinson S.E.
        • et al.
        Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk.
        Jama. 2011; 306: 1884-1890
        • Chlebowski R.T.
        • Anderson G.L.
        • Gass M.
        • et al.
        Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
        Jama. 2010; 304: 1684-1692
        • Chen W.Y.
        • Manson J.E.
        • Hankinson S.E.
        • et al.
        Unopposed estrogen therapy and the risk of invasive breast cancer.
        Arch Intern Med. 2006; 166: 1027-1032
        • Barańska A.
        • Błaszczuk A.
        • Kanadys W.
        • et al.
        Oral contraceptive use and breast cancer risk assessment: a systematic review and meta-analysis of case-control studies, 2009–2020.
        Cancers. 2021; 13: 5654
        • Owens D.K.
        • Davidson K.W.
        • Krist A.H.
        • et al.
        Medication use to reduce risk of breast cancer: US Preventive Services Task Force recommendation statement.
        Jama. 2019; 322: 857-867
        • National Comprehensive Cancer Network
        NCCN clinical practice guideline in oncology: breast cancer risk reduction. 2018;Version 2.
        (Available at:) (Accessed August 13, 2018)
        • Visvanathan K.
        • Hurley P.
        • Bantug E.
        • et al.
        Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
        J Clin Oncol. 2013; 31: 2942-2962
        • Saslow D.
        • Boetes C.
        • Burke W.
        • et al.
        American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.
        CA Cancer J Clin. 2007; 57: 75-89
        • Mandelblatt J.S.
        • Stout N.K.
        • Schechter C.B.
        • et al.
        Collaborative modeling of the benefits and harms associated with different US breast cancer screening strategies.
        Ann Intern Med. 2016; 164: 215-225
        • Oeffinger K.C.
        • Fontham E.T.
        • Etzioni R.
        • et al.
        Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society.
        Jama. 2015; 314: 1599-1614
        • Nelson H.D.
        • Pappas M.
        • Cantor A.
        • et al.
        Harms of breast cancer screening: systematic review to update the 2009 US Preventive Services Task Force recommendation.
        Ann Intern Med. 2016; 164: 256-267
        • Dabbous F.M.
        • Dolecek T.A.
        • Berbaum M.L.
        • et al.
        Impact of a false-positive screening mammogram on subsequent screening behavior and stage at breast cancer diagnosis.
        Cancer Epidemiol Prev Biomark. 2017; 26: 397-403
        • Siu A.L.
        • US Preventive Services Task Force
        Screening for breast cancer: US Preventive Services Task Force recommendation statement.
        Ann Intern Med. 2016; 164: 279-296
        • Vogel V.G.
        • Costantino J.P.
        • Wickerham D.L.
        • et al.
        Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer.
        Cancer Prev Res (Phila Pa. 2010; 3: 696-706
        • Goss P.E.
        • Ingle J.N.
        • Alés-Martínez J.E.
        • et al.
        Exemestane for breast-cancer prevention in postmenopausal women.
        N Engl J Med. 2011; 364: 2381-2391
        • Cuzick J.
        • Sestak I.
        • Forbes J.F.
        • et al.
        Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
        The Lancet. 2014; 383: 1041-1048
        • Farkas A.
        • Vanderberg R.
        • Merriam S.
        • et al.
        Breast cancer chemoprevention: a practical guide for the primary care provider.
        J Womens Health. 2020; 29: 46-56
        • Waters E.
        • et al.
        Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat. 134(2).
        (Available at:) (Accessed May 30, 2022)
        • Crew K.
        Addressing barriers to uptake of breast cancer chemoprevention for patients and providers. In: American society of clinical oncology educational book. Vol 35.
        (Available at:) (Accessed May 30, 2022)
        • Ropka M.E.
        • et al.
        Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 28(18).
        (Available at:) (Accessed May 30, 2022)